Please assess the completion status of the following clinical trial:

Trial Title: 18F-DCFBC PET/CT in Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Subject is greater than or equal to18 years old~* Platelet count \> 50,000/mm\^3~* Eastern Cooperative Oncology Group (ECOG) Performance score of 0 to 2.~* Ability to provide informed consent. All subjects must sign an informed consent form indicating their understanding of the investigational nature and risks of the study before any protocol-related studies are performed.~* Categories~  * ARM 1 only~    ---For patients with presumed localized disease (any tumor (T), nodes 0 (N0), metastasized 0 (M0)), a multiparametric magnetic resonance imaging (MRI) (standard of care at the National Institutes of Health ((NIH) Clinical Center) must be performed within 4 months of the N-\[N-\[(S)-1,3-dicarboxypropyl\]carbamoyl\]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC) (18F-DCFBC) injection with findings suggestive for prostate cancer and a prostate lesion at least 6mm or greater. Must have histopathologic confirmation of prostate cancer prior to 18F-DCFBC imaging.~ * ARM 2 only:~    * For patients status post radiation therapy for prostate cancer, any prostatic-specific antigen (PSA) increase from post radiation therapy nadir~   * OR~   * For patients status post prostatectomy, a PSA \>/=0.2 ng/ml~   * Nonspecific or no evidence for disease on standard imaging modality~ * ARM 3 only:~    * Patients must have identifiable metastatic disease on at least 1 clinically indicated imaging modality. If only soft tissue metastasis, one lesion must measure at least 6mm or greater. Patients must have confirmation of prostate cancer prior to 18FDCFBC imaging~Note: A patient who is eligible for one arm, subsequently may cross-over into a different arm.~EXCLUSION CRITERIA:~* Subjects for whom participating would significantly delay the scheduled standard of care therapy~* Subjects with any coexisting medical or psychiatric condition that is likely to interfere with study procedures and/or results.~* Subjects with severe claustrophobia unresponsive to oral anxiolytics~* Other medical conditions deemed by the principal investigator (or associates) to make the subject unsafe/ineligible for protocol procedures.~* Subjects weighing \> 350 lbs. (weight limit for scanner table), or unable to fit within the imaging gantry~* Serum creatinine \> 2 times the upper limit of normal~* Total bilirubin \> 2 times the upper limit of normal~* Liver transaminases (alanine aminotransferase (ALT), aspartate aminotransferase (AST)) greater than 3 times the upper limit of normal

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Suspected Localized Prostate Cancer (Type: EXPERIMENTAL): Patients with known localized prostate cancer with a soft tissue lesion at least 6mm or greater.
- Biochemical Recurrence (Type: EXPERIMENTAL): Patients with biochemical prostate cancer relapse after definitive treatment
- Known Metastatic Disease (Type: EXPERIMENTAL): Patients with identifiable metastatic disease on a conventional imaging modality. If only soft tissue metastasis, one lesion must measure 6mm or greater. Patients must have confirmation of prostate cancer prior to investigational imaging.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete